Research Focus: MET Pathway and MET-Inhibiting Anticancer Agents

Slide-based text module evaluating the oncogenic role of the Met pathway and new clinical data on the safety and efficacy of agents targeting this pathway.
Ravi Salgia, MD


Ravi Salgia, MD, provides expert perspective on results of studies of MET-targeted agents being evaluated in a variety of tumor types.

Ravi Salgia, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 27, 2012 Expiration: July 26, 2013

CCO Slideset

In this downloadable slideset, Ravi Salgia, MD, explores the role of the Met pathway in oncogenesis and reviews targeted agents in this setting across several tumor types.

Released: October 3, 2012
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Genentech BioOncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?